In the first half of 2025, China’s National Medical Products Administration (NMPA) intensified technical guidance for innovative medical device development and registration, resulting in 45 approved innovative medical devices—an 87.5% year-on-year increase. This surge reflects China’s booming medtech innovation landscape, powered in part by specialized CROs like CCRC Medtech, which facilitated 5 high-impact approvals in neurointervention, cardiovascular intervention, and pulsed-field ablation—fields with urgent clinical needs and high technical barriers.
CCRC-Medtech-Empowered Innovative Devices (H1 2025)
-
Peripheral Venous Thrombectomy Stent System (Import Registration No.: 20253030131)
-
Flow-Diverting Stent (Domestic Registration No.: 20253130732)
-
Cardiac Pulsed-Field Ablation System & Disposable Ablation Catheter (Domestic Registration Nos.: 20253010860 & 20253010879)
-
Pulmonary Artery Thrombectomy System (Import Registration No.: 20253030265)
Full-Lifecycle CRO Services: The “Innovation Accelerator”
As a strategic partner in medtech translation, CCRC Medtech integrates technical empowerment, process optimization, and compliance assurance across every stage—from concept validation to market approval:
-
Early-stage R&D: Cross-disciplinary clinical expertise and translational research guide precise product positioning.
-
Clinical trials: A nationwide network of top-tier sites and data-driven project management enable high-speed enrollment + real-time quality control.
-
Regulatory strategy: NMPA-focused pathway design with preemptive data supplementation and review-risk mitigation ensures faster, compliant approvals.
This end-to-end approach embodies CCRC Medtech’s core value: precision navigation, accelerated execution, and all-journey safeguarding for innovations.
Bridging the Translation Gap in High-Risk Innovation
Specializing in high-risk, high-reward devices, CCRC Medtech focuses on clinical-value-driven empowerment to propel breakthrough technologies from labs to clinics. Its mission: Reduce R&D uncertainty, shorten timelines, and accelerate patient access to frontier solutions. Moving forward, CCRC Medtech will continue refining its full-cycle services to help Chinese innovators overcome development bottlenecks—ensuring every high-value technology crosses the “valley of death” to benefit patients worldwide.
